Magnetic resonance guided adaptive Radiotherapy (MRgRT) for localised prostate cancer: The first result from a prospective international registry for the evidence-based Introduction of MRgRT
Teunissen, F. R. Willigenburg, T. Tree, A. C. Hall, W. A. Choi, S. L. Choudhury, Ananya Christodouleas, J. P. De Boer, J. C. J. De Groot-Van Breugel, E. N. Kerkmeijer, L. G. W.
Teunissen, F. R.
Willigenburg, T.
Tree, A. C.
Hall, W. A.
Choi, S. L.
Choudhury, Ananya
Christodouleas, J. P.
De Boer, J. C. J.
De Groot-Van Breugel, E. N.
Kerkmeijer, L. G. W.
Citations
Altmetric:
Abstract
Introduction & Objectives: Magnetic Resonance (MR) guided adaptive radiotherapy (MRgRT) is a new technique for treatment of localised
Prostate Cancer (PCa). MR-guided linear accelerator (MR-Linac) systems have been implemented in radiotherapy departments around the world.
However, the theoretical benefits of MRgRT still need to be confirmed in clinical practice. We report the short-term outcomes for the first PCa
patients treated within an international consortium on a 1.5T MR-Linac system with ultrahypofractionated radiotherapy.
Materials & Methods: Patients treated with 5x7.25 Gray were identified within the registry. Prostate Specific Antigen (PSA), Common Terminology
Criteria for Adverse Events (CTCAE) and Patient Reported Outcome (PRO) using the European Organisation for Research and Treatment of
Cancer (EORTC) Quality of Life Questionnaire (QLQ)-PR25, EORTC QLQ-C30 and the EuroQol EQ5D-5L were prospectively recorded at baseline
and at 3 and 6 months follow-up (FU). Descriptive and pairwise comparative statistics were conducted.
Results: One-hundred-and-fifty-six consecutive patients with localised PCa (13.2% low-, 77.2% intermediate-, and 9.6% high-risk [National
Comprehensive Cancer Network risk groups]) were included. Thirty-one patients (19.9%) received neoadjuvant Androgen Deprivation Therapy
(ADT). A significant decline of PSA in non-ADT patients was observed between baseline (median: 7.8 ng/mL), 3 months FU (median: 2.7 ng/
mL) and 6 months FU (median: 1.7 ng/mL) (p<0.001). No grade ≥3 Genitourinary (GU) and Gastrointestinal (GI) toxicity was reported (table). No
significant deterioration of PRO scores were observed. The percentage of men reporting no difficulty getting or maintaining an erection remained
constant throughout FU (44.4% at baseline, 40.0% at 3 months FU, and 42.9% at 6 months FU). Conclusions: Ultrahypofractionated 1.5T MR-Linac treatment of localised PCa is effective and safe (no grade ≥3 GU and GI toxicity). In the first 6
months following treatment, patients reported stable erectile function. No significant deterioration of PROs at 3- and 6-months FU was observed.
Description
Date
2021
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Teunissen FR, Willigenburg T, Tree AC, Hall WA, Choi SL, Choudhury A, et al. Magnetic Resonance guided adaptive Radiotherapy (MRgRT) for localised prostate cancer: The first result from a prospective international registry for the evidence-based Introduction of MRgRT. European Urology. 2021;79:S1486-S7.